Literature DB >> 23999562

The global epidemiology of herpes zoster.

Barbara P Yawn1, Don Gilden.   

Abstract

Varicella-zoster virus (VZV) is a ubiquitous, highly neurotropic, exclusively human α-herpesvirus. Primary infection usually results in varicella (chickenpox), after which VZV becomes latent in neurons of cranial nerve ganglia, dorsal root ganglia, and autonomic ganglia along the entire neuraxis. As humans undergo a natural decline in cell-mediated immunity (CMI) to VZV with age, VZV frequently reactivates to produce zoster, characterized by maculopapular or vesicular rash and dermatomal-distribution pain. Pain and rash usually occur within days of each other. Pain is severe and often burning. Colorful descriptions of zoster exist worldwide. In Arabic, Hezam innar ( ) means belt of fire; in Hindi, Baoisayaa daga ( ) means big rash; in Norwegian, Helvetesild means Hell's fire (also described as a bell of roses from Hell); and in Spanish, Culebrilla means small snake.(1) The most common complication of zoster is postherpetic neuralgia (PHN), operationally defined as pain lasting for more than 90 days after rash. Zoster may be followed by multiple neurologic disorders (meningoencephalitis, myelitis, and vasculopathy, including VZV temporal arteritis) as well as ocular disease (acute or progressive outer retinal necrosis).

Entities:  

Mesh:

Year:  2013        PMID: 23999562      PMCID: PMC3885217          DOI: 10.1212/WNL.0b013e3182a3516e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  A study of HIV seropositivity with various clinical manifestation of herpes zoster among patients from Karnataka, India.

Authors:  Kikkeri Narayanashetty Naveen; R S Tophakane; Keloji Hanumanthayya; Bhagawat Pv; Varadraj V Pai
Journal:  Dermatol Online J       Date:  2011-12-15

2.  Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.

Authors:  Peng-jun Lu; Gary L Euler; Rafael Harpaz
Journal:  Am J Prev Med       Date:  2011-02       Impact factor: 5.043

3.  Herpes zoster and quality of life: a self-limited disease with severe impact.

Authors:  E Lydick; R S Epstein; D Himmelberger; C J White
Journal:  Neurology       Date:  1995-12       Impact factor: 9.910

4.  Public awareness and knowledge of herpes zoster: results of a global survey.

Authors:  Esther Paek; Robert Johnson
Journal:  Gerontology       Date:  2009-09-17       Impact factor: 5.140

5.  A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

Authors:  Barbara P Yawn; Patricia Saddier; Peter C Wollan; Jennifer L St Sauver; Marge J Kurland; Lina S Sy
Journal:  Mayo Clin Proc       Date:  2007-11       Impact factor: 7.616

  5 in total
  75 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

2.  Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Authors:  Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox
Journal:  Int J Infect Dis       Date:  2014-03-25       Impact factor: 3.623

Review 3.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  [Diagnostics and management of herpes zoster ophthalmicus].

Authors:  R N Werner; N-I Steinhorst; A Nast; U Pleyer
Journal:  Ophthalmologe       Date:  2017-10       Impact factor: 1.059

5.  Zoster duplex: a clinical report and etiologic analysis.

Authors:  Feng Zhang; Jin Zhou
Journal:  Int J Clin Exp Med       Date:  2015-07-15

Review 6.  Neurological complications of varicella zoster virus reactivation.

Authors:  Maria A Nagel; Don Gilden
Journal:  Curr Opin Neurol       Date:  2014-06       Impact factor: 5.710

Review 7.  [Postherpetic neuralgia].

Authors:  G Goßrau
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

Review 8.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

9.  High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis.

Authors:  Elisabetta Xue; Hu Xie; Wendy M Leisenring; Louise E Kimball; Sonia Goyal; Lisa Chung; Rachel Blazevic; Byron Maltez; Anna Edwards; Ann E Dahlberg; Rachel B Salit; Colleen Delaney; Steven A Pergam; Michael Boeckh; Filippo Milano; Joshua A Hill
Journal:  Clin Infect Dis       Date:  2021-04-26       Impact factor: 9.079

Review 10.  Herpes Zoster in the Older Adult.

Authors:  Amrita R John; David H Canaday
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.